Reported Q: Q4 2024 Rev YoY: -6.6% EPS YoY: -258.8% Move: -7.06%
Cresco Labs Inc
CRLBF
$0.836 -7.06%
Exchange OTC Sector Healthcare Industry Drug Manufacturers Specialty Generic
Q4 2024
Published: Mar 14, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for CRLBF

Reported

Report Date

Mar 14, 2025

Quarter Q4 2024

Revenue

175.91M

YoY: -6.6%

EPS

-0.01

YoY: -258.8%

Market Move

-7.06%

Previous quarter: Q3 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $175.91M down 6.6% year-over-year
  • EPS of $-0.01 decreased by 258.8% from previous year
  • Gross margin of 46.9%
  • Net income of -4.37M
  • ""In 2024, we led with cash generation and operational excellence in order to shore up our profitable core."" - Charles Bachtell
CRLBF
Company CRLBF

Swipe to view all report sections

Executive Summary

Cresco Labs reported a Q4 2024 revenue of $175.9 million, a YoY decline of approximately 6.5% and a QoQ decline of 2.1%, with gross profit of $82.5 million and a gross margin of roughly 46.9%. The quarter featured continued price compression in core markets and supply constraints that constrained margin expansion, even as demand held up in several markets. For the full year, Cresco delivered $724 million in revenue (a ~6% YoY decline) but achieved material cash-flow improvements, including adjusted EBITDA of $200 million (up 15% YoY) and operating cash flow of $132 million, marking a record year for cash generation. The company attributes the operating cash flow strength to a sharpened focus on the quality of revenue, cost discipline, and portfolio optimization, while signaling near-term margin pressures as facilities ramp to meet rising demand, particularly in Illinois and Pennsylvania. Management outlined a three-pillar strategy: (1) strategic footprint expansion in core and select new markets (notably Kentucky), (2) leadership in branded wholesale across core markets, and (3) a productive Sunnyside retail platform with higher store productivity. In 2025, Cresco emphasizes cash generation, efficiency gains, and selective capital deployment, with Kentucky as a foundational expansion and several near-term investments expected to ramp in H2 2025 and beyond. The company also signaled debt-reduction objectives and a refinancing plan to improve financial flexibility.Overall, Cresco’s narrative centers on transitioning to sustainable profitability through volume-led growth in its core and new markets, higher operating leverage as capacity comes online, and disciplined capital allocation amid ongoing pricing pressures.

Key Performance Indicators

Revenue
Decreasing
175.91M
QoQ: -2.15% | YoY: -6.55%
Gross Profit
Decreasing
82.54M
46.92% margin
QoQ: -6.68% | YoY: -6.79%
Operating Income
Decreasing
19.41M
QoQ: -26.33% | YoY: -28.39%
Net Income
Decreasing
-4.37M
QoQ: 58.52% | YoY: -265.92%
EPS
Decreasing
-0.01
QoQ: 58.09% | YoY: -258.75%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q4 2024 175.91 -0.01 -6.6% View
Q3 2024 179.78 -0.03 -3.8% View
Q2 2024 184.36 -0.16 -6.8% View
Q1 2024 183.47 -0.02 -5.5% View
Q4 2023 188.24 0.01 -5.7% View